Pulmatrix, Inc. (NASDAQ:PULM) Sees Significant Growth in Short Interest

Pulmatrix, Inc. (NASDAQ:PULM) was the target of a large growth in short interest in June. As of June 30th, there was short interest totaling 91,267 shares, a growth of 816.4% from the June 15th total of 9,959 shares. Based on an average daily trading volume, of 194,642 shares, the short-interest ratio is presently 0.5 days. Currently, 2.5% of the shares of the company are sold short.

Institutional Trading of Pulmatrix

An institutional investor recently bought a new position in Pulmatrix stock. Dimensional Fund Advisors LP purchased a new stake in shares of Pulmatrix, Inc. (NASDAQ:PULM) in the third quarter, according to its most recent 13F filing with the SEC. The fund purchased 10,780 shares of the biotechnology company’s stock, valued at approximately $52,000. Dimensional Fund Advisors LP owned approximately 0.30% of Pulmatrix at the end of the most recent reporting period. Institutional investors own 11.84% of the company’s stock.

Pulmatrix Price Performance

Shares of PULM opened at $1.72 on Monday. The business’s 50-day moving average price is $1.45 and its 200-day moving average price is $1.88. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $6.83. The stock has a market cap of $6.28 million, a PE ratio of -1.40 and a beta of 1.90.

Pulmatrix (NASDAQ:PULM) last announced its quarterly earnings results on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pulmatrix in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Pulmatrix has a consensus rating of “Sell”.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).